Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
Clement Chan, MD
Assoc Clin Prof, Ophthalmology
School of Medicine
Research & Grantsmanship    Funded Research Project (PI)
  • SIRIUS Study For Neovascular Age-related Macular Degeneration ( 11/2006 - 12/2011 )
  • Age-related Eye Disease Study II (AREDS II) ( 10/2006 - 12/2011 )
  • Evaluation of Vitrectomy for Diabetic Macular Edema Study (Protocol D) ( 8/2006 - 12/2011 )
  • An Observational Study Of The Development Of Diabetic Macular Edema Following Scatter Laser Photocoagulation (Protocol F) ( 8/2006 - 12/2011 )
  • Fluocinolone Acetonide Intravitreal Inserts for Persistent Diabetic Macular Edema ( 3/2006 - 12/2011 )
  • Genentech Investigator Sponsor Trial: Intravitreal Ranibizumab (LucentisTM) for Vascularized Pigment Epithelial Detachment Associated With Age-related Macular Degeneration ( 11/2007 - 12/2010 )
  • Genentech BRAVO Study for Retinal Venous Occlusion (RVO) ( 8/2007 - 12/2010 )
  • Genentech RIDE Study for Diabetic Macular Edema (DME) ( 8/2007 - 12/2010 )
  • Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Study (Protocol I) ( 1/2007 - 12/2010 )
  • Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Study (Protocol J) ( 1/2007 - 12/2010 )
  • Laser Response Study (Protocol K) ( 1/2007 - 12/2010 )
  • Novartis Insight CNV Registry ( 7/2006 - 12/2010 )
  • Efficacy of MacugenTM in combination with VisudyneTM, EOP 1012 ( 11/2005 - 12/2010 )
  • Bevacizumab (AvastinTM) for neovascular age-related macular degeneration ( 10/2005 - 12/2010 )
  • Intravitreal triamcinolone for diabetic macular edema, a prospective controlled study (Protocol B) ( 10/2004 - 12/2010 )
  • SCORE for BRVO and CRVO, a prospective controlled study ( 5/2004 - 12/2010 )
  • PKC-beta MBDL Study for diabetic macular edema ( 1/2004 - 12/2010 )
  • Vitrectomy and sheathotomy for BRVO ( 1/2001 - 12/2010 )
  • Radial optic neurotomy for CRVO ( 1/2001 - 12/2010 )
  • Intravitreal triamcinolone for CRVO ( 1/2001 - 12/2010 )
  • Intravitreal triamcinolone for BRVO ( 1/2001 - 12/2010 )
  • Intravitreal triamcinolone for DDME ( 1/2001 - 12/2010 )
  • Intravitreal triamcinolone for CNV ( 1/2001 - 12/2010 )
  • Unilateral impending macular holes, an observational prospective study ( 1/1995 - 12/2010 )
  • Multi-center retrospective study on RPE tears associated with intravitreal bevacizumab (AvastinTM) for neovascular AMD ( 1/2006 - 10/2007 )
  • Subclinical Diabetic Macular Edema Study (Protocol G) ( 7/2006 - 12/2006 )
  • Bevacizumab (AvastintM) for diabetic macular edema (Protocol H) ( 6/2006 - 12/2006 )
  • Clinical Evaluation of Anti-angiogenesis in the Retina Intravitreal Trial AMD-2 (CLEAR-IT AMD-2) ( 2/2006 - 12/2006 )
  • Bevacizumab (AvastinTM) for neovascular age-related macular degeneration ( 10/2005 - 12/2006 )
  • Periocular triamcinolone for diabetic macular edema, a prospective controlled study (Protocol E) ( 10/2004 - 12/2006 )
  • Squalamine for neovascular age-related macular degeneration ( 10/2005 - 10/2006 )
  • Visudyne PDT registry, a retrospective study ( 1/2003 - 12/2004 )
  • Visudyne PDT registry, a prospective study ( 1/2003 - 12/2004 )
  • Phase III placebo-controlled double-masked prospective study on PDT with TIN-ethyletiopurpurin for treating subfoveal choroidal neovascularization due to AMD ( 1/2000 - 12/2004 )
  • Retinal complications after LASIK, a retrospective survey ( 1/1999 - 12/2004 )
  • Retinal complications after PRK ( 1/1999 - 12/2004 )
  • Macular holes after LASIK and PRK ( 1/1999 - 12/2004 )
  • Phase-III placebo-controlled double-masked prospective study of Intravitreal Vitrase (hyaluronidase) for treating vitreous hemorrhage ( 1/1999 - 12/2004 )
  • Phase III open label prospective study of intravitreal ISIS 2922 (Vitravene) for CMV retinitis associated with AIDS ( 1/1999 - 12/2001 )
  • Pneumatic detachment of the vitreous in the treatment of early idiopathic macular holes ( 1/1990 - 12/1995 )
  • Multi-center prospective study of pneumatic retinopexy for treating retinal detachment-Study #2 ( 1/1990 - 12/1995 )
  • Safety and toxicity study on alpha interferon for treatment of choroidal neovascularization ( 1/1992 - 12/1994 )
  • Innovative technique of repositioning dislocated posterior chamber implants ( 1/1986 - 12/1992 )
  • Supplemental photocoagulation on the buckle ( 7/1984 - 12/1985 )
  • Long-term assessment of ocular tolerance of intravitreal silicone oil ( 7/1984 - 12/1985 )
  • Acucela 4429-202 Study:  Safety and Efficacy Assessment Treatment TriaLs of Emixustat Hydrochloride (SEATTLE Clinical Trial)(A Phase 2b/3 Multicenter, randomized, double-Masked, dose-ranging Study comparing the efficacy and safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration).  Principal Investigator:  CK Chan ( 5/2013 - Present )
  • A Phase III comparison effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab for diabetic macular edema, a randomized clinical trial (Protocol T). ( 4/2013 - Present )
  • Genetic profiles for eyes with vascularized pigment epithelial detachment.

    ( 12/2012 - Present )

    Co-investigators: Drs.  P Abraham, D Sarraf, M Lalezary, SG Lin.  Support from Sequenom.

  • Intravitreal aflibErcept injection for the treatment of submacular Vascular pigmEnt epithelial detachmeNt (the EVEN Study).  Co-principal Investigator David Sarraf, MD

    ( 11/2012 - Present )

    Co-investigators Drs.: P. Abraham, SG Lin, M Lalezary

  • A Phase III evaluation of prompt panretinal photocoagulation (PRP) vs. ranibizumab-deferred panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) Study (Protocol S)

    ( 6/2012 - Present )
  • Regeneron’s VGFTe-RVO-1027 (VIRANT): A double-masked, randomized, active-controlled study of the efficacy, safety, and tolerability of intravitreal administration of VEGF Trap-Eye (aflibercept injections [IAI]) in patients with macular edema secondary to branch retinal vein occlusion.

    ( 4/2012 - Present )
  • Regeneron’s VGFT-OD-1009 (VISTA): A double-masked, randomized, active-controlled, Phase III Study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema.

    ( 8/2011 - Present )
  • Part 2:  Genetic study (DNA extraction and genotyping) for single nucleotide polymorphisms (SNP) for genes associated with vascular endothelium growth factor, complement Factor H, Factor B, Factor 2, Bactor C3, and Factor C5, etc. 

     

    ( 8/2011 - Present )
  • A Phase II evaluation of topical NSAIDS in eyes with non-center involved diabetic macular edema (Protocol R)

    ( 0/2011 - Present )
  • Genentech’s HARBOR Study, A Phase III, multicenter, randomized, double-masked study comparing the efficacy and safety
    of 0.5-mg and 2.0-mg ranibizumab
    administered monthly or on as needed basis, in patients with subfoveal neovascular age-related macular degeneration

    ( 12/2010 - Present )
  • Intravitreal ranibizumab for vitreous hemorrhage from proliferative diabetic retinopathy study (Protocol N)

    ( 0/2010 - Present )
  • An Evaluation of Intravitreal Triamcinolone Acetonide in Individuals with Diabetic Retinopathy Undergoing Cataract Surgery (Protocols P and Q)

    ( 0/2009 - Present )
  • Part 1:  Intravitrea ranibizumab (high-dose[2.0mg] vs. conventional[0.5mg]) for vascularized pigment epithelial detachment associated with age-related macular degeneration. 

    ( 9/2008 - Present )
  • Genentech CRUISE Study for Retinal Venous Occlusion (RVO) ( 8/2007 - Present )
  Funded Research Project (CI)
  • Posurdex for neovascular age-related macular degeneration ( 8/2005 - 12/2010 )
  • Family Study Of Age-related Macular Degeneration ( 1/1996 - 12/2010 )
  • External co-investigator for AREDS I ( 1/1995 - 12/2000 )
  • Evaluation of OCT and visual acuity outcomes after initial loading doses with intravitreal afibercept injection at 6 months in patients previously treeated with ranibizumab or bevacizumab therapy for exudative age-related macular degeneration.  An independent retrospective study.  Principal Investigator: A Jain, MD

    ( 11/2012 - Present )
  • Pharmacokinetic profile of the VEGF inhibitor aflibercept (Eylea) associated with intravitreal injection.  Drug level testing site:  University of Bonn, Germany.  Principal Investigator: Carl Meyer, MD

    ( 11/2012 - Present )
  Grant Proposals--Funded
  • Travel Grant for paper presentation at the XXVII Jules Gonin's International Retina Society meeting in Kyoto, Japan.  Grant of $2,500 from the Society.

    ( 11/2010 )
  • Evaluation of OCT and visual acuity outcomes after initial loading doses with intravitreal afibercept injection at 6 months in patients previously treeated with ranibizumab or bevacizumab therapy for exudative age-related macular degeneration.  Funded by Regeneron for $48,375.

    ( 11/2012 - Present )
  • Intravitreal aflibErcept injection for the treatment of submacular Vascular pigmEnt epithelial detachmeNt (the EVEN Study).  Grant from Regeneron:  $303,490.

    ( 11/2012 - Present )
  • Part 2:  Genetic study (DNA extraction and genotyping) for single nucleotide polymorphisms (SNP) for genes associated with vascular endothelium growth factor, complement Factor H, Factor B, Factor 2, Bactor C3, and Factor C5, etc.  Awarded budget:  $141,802. Funded by Genentech.

    ( 8/2011 - Present )
  • Part 1:  Intravitrea ranibizumab (high-dose[2.0mg] vs. conventional[0.5mg]) for vascularized pigment epithelial detachment associated with age-related macular degeneration.  Genentech Grant FVP4332s; awarded budget:  $419,240.  Additional funding from Owen Locke Memorial Foundation:  $100,000.

    ( 9/2008 - Present )